brain disease: A disease affecting the brain or part of the brain.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
80 |
4. Check minimum number of eventsNone |
80 |
5. Include endpointsNone |
80 |
6. Filter based on genotype QC (FinnGen only) |
73 |
Control definitions (FinnGen only)
- Control exclude
- G6_OTHNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G93
- Name in latin
- Oedema cerebri
Similar endpoints
↥List of similar endpoints to
Cerebral oedema
based on the number of shared cases.
Similar with more cases:
- Other neurological diseases
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 918 | 430 | 478 |
| Only index persons | 515 | 232 | 283 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 50.49 | 52.34 | 48.62 |
| Only index persons | 51.71 | 52.78 | 50.83 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 73 | 38 | 35 |
| Unadjusted period prevalence (%) | 0.01 | 0.01 | 0.02 |
| Median age at first event (years) | 56.02 | 55.98 | 56.06 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 78
- Matched controls
- 780
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G93.6
ICD-10 Finland
Cerebral oedema
+∞
106.7
76
*
N03AX14
ATC
levetiracetam; systemic
58.7
28.0
32
9
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
14.6
27.2
30
32
AA1AD
NOMESCO Finland
CT of head and brain
9.7
23.0
51
127
130
Kela drug reimbursment
Malignant tumour
10.0
18.7
26
37
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
42.8
18.2
22
7
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
23.8
17.6
25
15
H02AB02
ATC
dexamethasone; systemic
7.9
17.0
31
60
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
53.3
14.8
17
*
L01AX03
ATC
temozolomide; systemic
66.0
14.4
16
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
6.3
13.5
31
74
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
61.0
13.4
15
*
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
6.1
12.2
28
66
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
6.0
12.0
28
67
N03AX18
ATC
lacosamide; systemic
76.8
12.0
13
*
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
30.7
10.2
13
5
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.9
9.4
20
43
R56.8
ICD-10 Finland
Other and unspecified convulsions
10.8
9.4
18
21
AAK80
NOMESCO Finland
Partial excision of skull cap
+∞
8.5
8
*
G40.9
ICD-10 Finland
Epilepsy, unspecified
17.4
8.0
12
8
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
17.4
8.0
12
8
WX882
NOMESCO Finland
High dependency care
13.9
7.9
13
11
A04AA01
ATC
ondansetron; systemic, rectal
7.3
7.9
19
33
PA2CC
NOMESCO Finland
Cerebral very extensive angiography with X-ray
88.1
7.6
8
*
D43.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Brain, supratentorial
88.1
7.6
8
*
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
88.1
7.6
8
*
WF002
NOMESCO Finland
Radical radiotherapy
9.5
7.5
15
19
AAF00
NOMESCO Finland
Ventriculostomy
+∞
7.4
7
*
C71.1
ICD-10 Finland
Malignant neoplasm: Frontal lobe
+∞
7.4
7
*
AAK00
NOMESCO Finland
Cranioplasty
+∞
7.4
7
*
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
+∞
7.4
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.9
7.3
28
97
A03FA01
ATC
metoclopramide; systemic, rectal
3.9
7.3
29
103
ZXC95
NOMESCO Finland
Use of surgical navigator
25.1
6.8
9
*
WX872
NOMESCO Finland
Intensive care
11.6
6.8
12
12
C71.23
ICD-10 Finland
Malignant tumor of temporal lobe grade IV glioma
75.8
6.5
7
*
I69.0
ICD-10 Finland
Sequelae of subarachnoid haemorrhage
75.8
6.5
7
*
R51.80
ICD-10 Finland
Headache
3.9
6.5
24
80
A04AA02
ATC
granisetron; systemic, transdermal
6.6
6.1
15
27
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
34
81
6.67
15.02
17.5
7.8
1.32
0.98
mmol/l
0.20
26
69
9
0
+∞
9.56
1.0
0.0
—
—
—
0
0
11
5
25.19
8.27
1.6
2.2
—
—
—
0
0
14
15
11.09
7.66
2.9
1.4
590.21
488.87
mg/l
0.30
14
15
31
115
3.81
7.28
4.4
2.8
144.00
440.89
ng/l
0.55
24
82
30
114
3.65
6.73
2.7
2.0
—
—
—
0
0
33
140
3.35
6.16
2.7
2.6
—
—
—
0
0
24
90
3.41
5.37
2.5
1.7
—
—
—
0
0
51
297
3.07
5.30
3.3
2.7
—
—
estimate
—
0
0
18
57
3.81
5.15
36.5
17.5
24.28
25.28
mmol/l
0.60
18
57
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
11
17
7.34
4.97
2.4
3.7
0.36
0.33
iu/ml
—
6
7
8
9
9.74
4.39
4.5
1.0
37.13
17.63
ug/l
—
8
9
21
83
3.09
4.23
2.6
1.8
—
—
—
0
0
26
119
2.78
4.02
9.6
5.0
0.81
0.81
mmol/l
0.02
26
111
15
53
3.27
3.59
24.6
10.3
95.51
93.01
%
1.11
15
53
6
6
10.69
3.56
1.3
1.0
—
—
—
0
0
57
399
2.59
3.46
21.1
11.3
4.71
4.09
e9/l
0.30
51
346
6
7
9.15
3.32
1.2
1.0
—
—
—
0
0
21
96
2.63
3.19
4.3
3.5
3.79
3.24
e6/l
—
10
49
10
26
4.25
3.11
2.0
2.5
—
—
—
0
0
5
5
10.55
3.02
1.0
1.2
279.00
260.20
mg/l
—
5
5
12
38
3.54
3.01
2.4
1.6
—
—
—
0
0
5
6
8.79
2.79
1.0
1.0
—
—
—
0
0
52
375
2.16
2.59
14.9
6.5
12.44
11.54
umol/l
0.18
52
356
36
228
2.08
2.51
4.1
3.4
61.56
29.74
u/l
0.88
36
211
20
100
2.34
2.49
18.7
10.2
105.30
103.57
mmol/l
0.74
20
100
6
14
4.55
2.19
1.8
1.6
—
—
—
0
0
6
14
4.55
2.19
1.8
1.6
—
—
—
0
0
9
31
3.15
2.15
3.3
1.9
90.44
99.35
%
—
9
31
7
20
3.74
2.11
3.1
2.1
—
—
—
0
0
7
25
2.97
1.69
3.9
2.3
265.43
176.24
%
—
7
25
19
109
1.98
1.65
4.1
3.2
0.90
0.75
e6/l
—
8
60
67
729
0.43
1.59
51.8
23.5
90.50
90.68
fl
0.14
67
721
67
729
0.43
1.59
56.8
24.4
39.33
40.84
%
2.24
67
720
67
729
0.43
1.59
52.4
23.7
131.75
136.91
g/l
2.22
67
721
11
52
2.30
1.53
29.4
8.4
1.76
1.02
mmol/l
0.88
11
44
5
16
3.26
1.46
1.0
1.1
106.40
111.88
%
—
5
16
5
16
3.26
1.46
2.2
1.8
—
—
—
0
0
5
16
3.26
1.46
1.0
1.9
—
—
—
0
0
5
22
2.36
1.05
2.2
1.7
—
—
—
0
0
5
22
2.36
1.05
1.0
1.8
—
—
—
0
0
9
48
1.99
1.05
2.0
1.8
—
—
—
0
0
65
701
0.56
0.95
22.6
11.9
36.58
27.00
u/l
1.37
65
687
66
707
0.57
0.87
42.9
19.4
66.80
78.27
umol/l
3.92
66
700
34
269
1.47
0.86
3.5
3.9
18.74
34.83
ng/l
1.18
28
188
5
95
0.49
0.85
1.8
2.3
—
—
—
0
0
0
26
0.00
0.80
0.0
1.8
—
2.90
—
0
19
0
27
0.00
0.79
0.0
1.1
—
1.50
—
0
16
5
23
2.25
0.77
4.0
1.9
—
—
—
0
0
7
38
1.92
0.76
1.0
1.3
—
—
—
0
0
5
25
2.07
0.74
3.2
2.0
—
—
—
0
0
5
26
1.98
0.72
3.8
2.1
—
—
—
0
0
5
29
1.77
0.65
1.0
4.7
26.48
24.42
mmol/l
—
5
29
7
114
0.58
0.64
4.6
2.8
2.27
2.35
g/l
—
7
104
23
178
1.41
0.63
5.5
3.5
0.21
0.33
e6/l
0.31
13
132
8
52
1.60
0.62
19.8
11.5
25.00
24.72
mmol/l
—
8
52
5
86
0.55
0.60
2.8
1.6
—
—
—
0
0
24
192
1.36
0.54
3.9
4.1
3.09
7.96
mg/mmol
1.12
15
124
7
109
0.61
0.53
4.6
2.9
22.69
23.59
%
—
7
102
7
48
1.50
0.48
11.0
6.8
76.71
98.70
ng/l
—
7
41
0
15
0.00
0.41
0.0
4.0
—
39.39
—
0
15
9
66
1.41
0.40
5.1
4.3
6.98
8.57
ug/l
—
9
55
6
41
1.50
0.37
2.2
2.9
—
—
—
0
0
6
88
0.66
0.35
2.2
2.2
—
—
—
0
0
6
45
1.36
0.34
2.0
8.1
0.88
1.38
%
—
6
45
6
46
1.33
0.34
2.3
2.8
—
—
—
0
0
26
226
1.23
0.30
5.2
3.8
—
—
—
0
0
40
365
1.20
0.28
4.0
4.1
0.00
0.00
estimate
—
6
69
6
80
0.73
0.25
3.3
6.5
—
—
—
0
0
5
40
1.27
0.23
1.2
3.6
4.86
4.65
pmol/l
—
5
34
39
361
1.16
0.21
4.1
4.1
0.00
0.00
estimate
—
6
69
0
11
0.00
0.21
0.0
2.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
6.5
—
161.80
—
0
10
0
12
0.00
0.21
0.0
1.5
—
48.54
—
0
12
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
54
561
0.88
0.15
51.0
19.0
13.73
13.53
%
0.60
54
556
65
667
0.85
0.14
49.5
18.5
3.96
3.98
mmol/l
0.27
65
655
39
369
1.11
0.13
4.2
4.1
0.80
0.06
estimate
—
5
66
15
167
0.87
0.12
2.7
4.0
23.51
22.89
%
—
8
68
65
664
0.87
0.10
49.9
18.3
138.68
139.68
mmol/l
1.55
65
653
45
466
0.92
0.09
3.7
3.4
—
—
—
0
0
6
57
1.06
0.09
1.2
1.3
—
—
—
0
0
26
274
0.92
0.07
2.5
2.1
88.85
98.60
pmol/l
0.62
15
140
15
143
1.06
0.01
1.3
1.8
—
—
—
0
0
66
654
1.06
0.01
39.7
15.9
23.22
23.25
mg/l
0.00
66
535
12
123
0.97
0.00
1.3
1.7
466.29
114706347.05
pmol/l
—
7
102
49
492
0.99
0.00
3.6
4.6
15.76
14.81
pmol/l
1.13
49
454
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
4.2
—
1.60
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
12.83
—
0
6
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
17.97
—
0
5
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
1920.17
—
0
6
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_CEROEDEMA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CEROEDEMA | 9.279 [2.77, 31.05] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.032 |
During the follow-up period (1.1.1998 — 31.12.2019), 68 out of 166 females with G6_CEROEDEMA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_CEROEDEMA | 10.985 [5.1, 23.68] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.023 |
During the follow-up period (1.1.1998 — 31.12.2019), 79 out of 184 males with G6_CEROEDEMA died.
Mortality risk
Mortality risk for people of age
years, who have G6_CEROEDEMA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.852% | 1.959% |
| 5 | 4.155% | 10.695% |
| 10 | 11.262% | 27.797% |
| 15 | 21.457% | 48.394% |
| 20 | 33.987% | 69.973% |
Relationships between endpoints
↥Index endpoint: G6_CEROEDEMA – Cerebral oedema
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data